NCT00567008

Chantix for Treating Cocaine Dependence

A Double-Blind Placebo-Controlled Pilot Trial of Varenicline (Chantix) for the Treatment of Cocaine Dependence

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: University of Pennsylvania · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether varenicline (Chantix), is effective for the treatment of cocaine dependence.

Detailed description

The purpose of study is to determine if Varenicline (Chantix™) promotes cocaine abstinence in cocaine dependent individuals. Varenicline (Chantix™) (2.0 mg/day) or placebo will be administered in a 9-week double-blind trial to patients meeting diagnostic criteria for cocaine dependence.

Conditions

• Cocaine Dependence

Interventions

Type	Name	Description
DRUG	varenicline	1.0 mg BID for 8 weeks
DRUG	placebo	placebo BID for 8 weeks

Timeline

• Start date: 2007-12-01
• Primary completion: 2009-09-01
• Completion: 2009-09-01
• First posted: 2007-12-04
• Last updated: 2013-11-07
• Results posted: 2013-11-07

Locations

1 site across 1 country: United States